| 2020 | 2021 | 2022 | 2023 (projected) | Interest Expense | 96K | 14K | 12.6K | 12.9K | Gross Profit | 10.4M | 12.6M | 10.0M | 10.4M |
Ownership Breakdown
| Retail Investors66.38% | Insiders16.93% | Institutions16.69% |
| Retail Investors | 66.38 | |
| Insiders | 16.93 | |
| Institutions | 16.69 |
Will Vivos TherapeuticsInc (USA Stocks:VVOS) turn things around in January?
 | By Aina Ster | Macroaxis Story |
Hope springs eternal in the human breast, and investors in Vivos Therapeutics Inc (NASDAQ: VVOS) may be cautiously optimistic for a turnaround this January. The company, operating in the Medical Devices sector within the Healthcare industry, has faced significant challenges, reflected in a substantial net income loss of **$23.8 million** and a negative profit margin of **1.06%**. Despite these hurdles, the gross profit stands at a more encouraging **$12.6 million**, suggesting that the company has some underlying strengths to build upon. With a market capitalization of **$26.5 million**, Vivos Therapeutics has a relatively small footprint in the Health Care Equipment & Supplies space, but its team of 154 full-time employees is dedicated to turning the tide. The company's EPS estimate for the current year is a loss of $11.48, and the forecast for the next year remains in the red at a loss of $4.62, indicating that the path to profitability may still be a work in progress. However, the analyst's highest estimated target price of $17.5 offers a glimmer of hope for a significant upside, although it's important to note the possible downside price of $0.2, which underscores the high-risk nature of this investment. As the fiscal year end approaches in December, stakeholders will be watching closely to see if Vivos can leverage its assets and market position to improve its financial health and reward patient investors. At present, Vivos Therapeutics Inc.'s debt-to-equity ratio remains relatively stable compared to the previous year. The company's gross margin is projected to improve to 0.63 in 2023, while its earnings before tax are expected to decline to a negative $25.7 million in the same year.
Given the growing interest in the healthcare equipment and supplies sector, it is worthwhile to examine Vivos Therapeutics Inc. In January, we will explore the potential for transforming Vivos Therapeutics Inc. into a consistently growing entity. Additionally, I will discuss several fundamental indicators that investors in Vivos Therapeutics Inc. should consider in January.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
Vivos Therapeutics Inc is currently perceived as overvalued with a share price of $18.35, given the modest growth projections ahead. The company has been assigned a performance score of 8 out of a possible 100, according to a specific performance evaluation metric.
The stock has a beta of -1.0038, suggesting a relatively high level of risk compared to the overall market. This implies that as the market sentiment turns more bullish, the returns on Vivos Therapeutics Inc may decline gradually. Conversely, in times of market volatility, Vivos Therapeutics Inc might slightly outperform the market.
To determine whether the expected return of 12.1% for Vivos Therapeutics Inc is likely to be sustained in the future, twenty-one different technical indicators have been analyzed. These indicators can assist in verifying the sustainability of the expected returns. Investors should consider using the standard deviation of Vivos Therapeutics Inc, along with examining the relationship between the value at risk and kurtosis, to better understand and forecast future returns on the stock.
Main Takeaways
Investors eyeing Vivos Therapeutics Inc (NASDAQ: VVOS), a player in the Medical Devices sector within the Healthcare industry, are cautiously optimistic about a potential turnaround. Despite an operating loss of 25M and a concerning EPS estimate for the current quarter at a loss of 3.12, there are factors that could signal a brighter horizon. With a modest market capitalization of 26.5M, Vivos Therapeutics showcases a product portfolio in the health care equipment and services domain that could be on the cusp of gaining traction. The company's commitment to innovation in this space, coupled with a dedicated team of 154 full-time employees, may be pivotal in reversing its fortunes. However, investors should be mindful of the company's financials and consider the high risk-reward profile indicated by a Total Risk Alpha of 1.93 before making any investment decisions. The performance of Vivos Therapeutics in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Vivos Therapeutics' stock prices. When investing in Vivos Therapeutics, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Vivos Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Vivos Therapeutics carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.How important is Vivos Therapeutics's Liquidity
Vivos Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Vivos Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Vivos Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Vivos Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Vivos Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Vivos Therapeutics's total debt and its cash.
Vivos Therapeutics Gross Profit
Vivos Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Vivos Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Vivos Therapeutics Gross Profit growth over the last 10 years. Please check Vivos Therapeutics' gross profit and other fundamental indicators for more details.
A Deeper look at Vivos
The market capitalization of Vivos TherapeuticsInc is currently $26.51 Million. Vivos TherapeuticsInc has 16.93 % of its outstanding shares held by insiders and 16.69 % owned by institutional holders. Be advised that no matter how volatile the entity is, if the real value of the company is more than the value suggested by the market, you should consider buying it.
The only limit to our realization of tomorrow will be our doubts of today. Franklin D. Roosevelt's words resonate as investors consider the future of Vivos Therapeutics Inc (NASDAQ: VVOS), a company in the competitive medical devices industry.With a current ratio of 3.15X, Vivos appears to have a solid footing in terms of short-term financial stability. However, the company's financial performance paints a challenging picture, with a net loss from continuing operations of **$23.8 million** and an EBITDA of **-$18.6 million**. Despite these figures, the company's market capitalization stands at $26.51 million, suggesting that some investors still see potential in its underlying value. The stock's Beta of 2.75 indicates high volatility, yet with a Wall Street target price of $6, there's an implied potential upside. As January unfolds, the question remains whether Vivos can leverage its assets, including a net asset value of $13.72 million, to engineer a turnaround that justifies investor optimism. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Vivos Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.